Latest Paragon Care (ASX:PGC) News

AdAlta led the healthcare board after a US cell-therapy manufacturing deal gave its automation platform commercial credibility, while Vectus fell despite reporting a profit. Clinical trial updates, diagnostic launches and fresh funding plans kept the sector active.

Paragon Care has lined up an on-market buy-back of up to 82.8 million shares, worth about $10.8 million at the latest closing price, while its employee trust can acquire a further 23.9 million shares. The transactions give the healthcare group two sizeable tools for managing its capital and incentive plans, although neither maximum is guaranteed to be completed.

Healthcare shares split sharply this week, with Biome Australia rising while Nanosonics, Epiminder and Saluda Medical fell heavily.
Profits, trial progress and new approvals competed with cash needs, debt concerns and weaker investor confidence.

ParagonCare’s FY26 results show modest revenue and underlying earnings growth, overshadowed by a large credit loss provision related to the Infinity Pharmacy Group debt.

Healthcare stocks split into two camps this week. Buyers chased clear commercial wins, while several halted names gave back early excitement once trading resumed. The biggest moves came from a collapse in Opthea, a surge in Control Bionics, and a strong jump in Biome Australia after a margin-boosting manufacturing deal.

ParagonCare anticipates recovering up to 32.5% of its exposure to the insolvent Infinity Retail Pharmacy Group, while maintaining a steady FY26 earnings outlook amid cost pressures.

Receivers and administrators have been appointed to 54 pharmacies within the Infinity Retail Pharmacy Group, catching Paragon Care off guard despite ongoing debt restructuring talks. The company pledges to support an orderly resolution to maximise creditor returns.

Paragon Care Limited is set to acquire Indonesian medical aesthetics leader Haju Medical for A$70 million, aiming to boost its footprint across Asia Pacific and accelerate growth in the aesthetics sector.

ParagonCare reported solid FY25 results, progressing well on its complex merger integration and expanding its footprint in Asia through the acquisition of Somnotec Group.

ParagonCare has released its audited FY25 financial results, confirming steady profit while revealing a significant reclassification of debt and ongoing challenges with a major retail pharmacy receivable.

ParagonCare Limited reported a solid FY25 with $3.6 billion in revenue and $95.2 million underlying EBITDA, marking progress in its integration and growth strategy across Asia Pacific. The company is poised for further profitability improvements and expansion in FY26.

Paragon Care Limited reported solid FY25 results with revenue climbing to $3.61 billion and underlying EBITDA rising 3%, driven by successful integration and expansion into new healthcare segments.